title: [Clinical consensus on respiratory syncytial virus (RSV) infection prophylaxis and the use of palivizumab in paediatric cardiology.].
abstract: BACKGROUND
  Following the results of the CIVIC study, the SECPCC proposes to revise its recommendations for the prevention of RSV, taking into account the new evidence, as well as the preventive experience of paediatric cardiologists. For this purpose a structured method of professional consensus has been chosen.
  
  
  OBJECTIVE
  To develop a Spanish clinical consensus on preventing infection by RSV under the auspices of the Sociedad Española de Cardiología Pediátrica y Cardiopatías Congénitas.
  
  
  METHODS
  Delphi Consensus modified in two rounds. The study was conducted in four phases: 1) constitution of a Scientific Committee for bibliographic review and submission of the recommendations for discussion, 2) constitution of an Expert Panel with 75 representatives in the speciality, 3) postal survey organised in two rounds and intermediate processing of opinions, and issuing of a report to the panellists, and 4) discussion of the results in a face-to-face meeting of the Scientific Committee.
  
  
  RESULTS
  Consensus was reached on 54 of the 70 preventive recommendations analysed. With respect to the 16 remaining issues, no consensus was reached, due to differences in professional opinion and the absence of established criteria among the majority of the experts.
  
  
  CONCLUSIONS
  A set of recommendations for RSV prophylaxis in cardiology was developed and updated, rated in accordance with the degree of professional consensus on which they were based. These can be considered valid until such time as new scientific information emerges that warrants a further review.
authors.affiliation: Cardiología Pediátrica, Hospital General Universitario Gregorio Marañón, Madrid, España. ggallardo@luzan5.es
authors.forename: C
authors.initials: C
authors.lastname: Medrano López
authors.forename: L
authors.initials: L
authors.lastname: García-Guereta
authors.forename: L
authors.initials: L
authors.lastname: Fernández Pineda
authors.forename: P
authors.initials: P
authors.lastname: Malo Concepción
authors.forename: E
authors.initials: E
authors.lastname: Maroto Alvaro
authors.forename: J
authors.initials: J
authors.lastname: Santos de Soto
authors.forename: J
authors.initials: J
authors.lastname: Lirio Casero
authors.forename: P
authors.initials: P
authors.lastname: Suárez Cabrera
authors.forename: F
authors.initials: F
authors.lastname: Caballero Martínez
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000627:therapeutic use*; D002648:Child; D006801:Humans; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab